Victrex Gains FDA Nod for PEEK Knee System Study
Company Announcements

Victrex Gains FDA Nod for PEEK Knee System Study

Victrex (GB:VCT) has released an update.

Victrex plc has announced a partnership with Maxx Orthopedics Inc, receiving FDA approval for a clinical study of their innovative PEEK-OPTIMA™ Femoral Knee Component in the US. This study aims to demonstrate the advantages of the PEEK Knee system over traditional metal components, building on positive international trials. The company anticipates entering the Indian market in 2025, with further interest from the medical device industry globally.

For further insights into GB:VCT stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks UK Auto-Generated NewsdeskVictrex PLC Announces Current Share Capital
TipRanks UK Auto-Generated NewsdeskVictrex PLC Reports Major Stake Increase by M&G Plc
TipRanks UK Auto-Generated NewsdeskVictrex Director Buys Shares, Signals Confidence
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App